June 29, 2026
The Drug Enforcement Administration told a federal appeals court on Tuesday, August 11, 2026 that the hemp company challenging its treatment of hexahydrocannabinol has no right to be in court at all. In a brief filed in the U.S. Court of Appeals for the Fourth Circuit, DEA argued that Bluestar Operations, LLC lacks standing to petition for review of the agency's May 2026 rule, and that even if it had standing, it would lose. The filing is signed by DEA Administrator Terrance Cole.
The rule at the center of the case is narrow on its face. Until May 2026, HHC was tracked under the same DEA drug code as tetrahydrocannabinols generally. The rule gave HHC its own separate listing and its own code in Schedule I of the Controlled Substances Act.
DEA's brief leans hard on that narrowness. HHC, the agency wrote, “is a synthetic hallucinogenic drug that for decades has been included in schedule I under the Controlled Substances Act (CSA).” Assigning it a code is “a technical change that has no substantive effect on HHC's status as a schedule I substance.” Because the rule “imposes no new obligations or liabilities,” DEA argued, Bluestar has not “identified any injury traceable to the rule that can be remedied in this proceeding.”
The agency then made the argument that matters most to operators: “Even if this Court were to grant Bluestar's requested remedy and vacate the final rule, HHC still would be a schedule I substance as a THC.”
Here is the part the wire coverage does not spell out. DEA's position is structurally self-reinforcing. The agency says the rule changed nothing, therefore no one was injured by it, therefore no one can challenge it. But the reason HHC sellers believe they were injured is precisely the underlying classification that DEA says the rule merely restates — a classification that was never itself promulgated through a challengeable rulemaking.
Win or lose on the merits, that framing pushes the real question out of the appellate posture and into some future enforcement action, where a defendant argues product by product that its specific HHC is hemp. DEA said as much: “Bluestar remains free to argue that its HHC qualifies as hemp in an appropriate case.” For a business, an “appropriate case” means a seizure, a prosecution or a civil enforcement proceeding. That is a materially worse forum than a petition for review, and it is why this brief matters more than its procedural framing suggests.
DEA also conceded a point worth reading closely: “Bluestar does not even claim that the listing of HHC in schedule I is categorically unlawful. Bluestar claims only that its specific products are hemp and therefore exempt from schedule I.” The agency is right that this is a product-specific dispute. It is also the reason a favorable ruling for Bluestar would not settle the category.
Two petitions are live. Bluestar Operations, LLC is in the Fourth Circuit, which denied its request for a stay of the rule in June — the products stay in Schedule I while the case proceeds. IHC Investments, Inc. brought a parallel challenge in the Ninth Circuit. We covered both petitions when they were filed.
The circuit split potential is not accidental. Bluestar leans on a Fourth Circuit decision holding that hemp-derived THC-O-acetate is federally legal despite DEA's contrary view. IHC leans on the Ninth Circuit's 2022 delta-8 decision reading the 2018 Farm Bill's language expansively. Both petitions argue the major questions doctrine: that banning a category worth billions requires clear congressional authorization, not agency interpretation. In a reply this month, Bluestar said DEA is “unable to defend the merits of treating hemp-derived HHC as a Schedule I controlled substance — a position contrary to binding Circuit precedent.”
DEA's counter-position is a definitional one it has held since at least a 2023 letter from its Drug and Chemical Evaluation Section: HHC “does not occur naturally in the cannabis plant and can only be obtained synthetically.” In the rule itself the agency wrote that “tetrahydrocannabinols produced through chemical conversion, even when hemp derived, are considered synthetically produced” and fall outside the hemp exclusion. Commercial HHC is made by hydrogenating hemp-derived CBD, which puts essentially the entire commercial supply on DEA's side of that line. The Department of Health and Human Services concurred in the listing.
This is the sequencing consequence operators keep missing. Much of the industry is watching whether the hemp recriminalization date moves from November 12 to December 11, 2026 — the Senate has passed a delay, the House has not acted, and it is not law. Read the December 11 delay fight for the mechanics.
For HHC, the delay is beside the point. DEA's stated position is that HHC is Schedule I today, independent of any Farm Bill deadline, because it is synthetic. A delay to the hemp redefinition changes the date on which other cannabinoids lose their exemption. It does not confer an exemption HHC, on DEA's reading, never had. DEA underlined the asymmetry itself, telling the court Bluestar's theory “will soon be overtaken by events” because the coming recriminalization “will defeat whatever remains of Bluestar's claims.”
Translated: DEA thinks it wins on the calendar even if it loses in court. An HHC seller planning around December 11 is planning around the wrong risk.
The United States is not an outlier here, and that is worth knowing if you export. A United Nations drug control body added HHC to Schedule II of the 1971 Convention on Psychotropic Substances last year; the U.S. was the only country to abstain from that vote. Europe moved earlier and harder — see Europe's semi-synthetic cannabinoid crackdown and the current picture in the UK and EU.
Domestically, contrast the federal posture with what states do on their own timetable. Virginia's 2 mg per-package cap took effect August 15 and catches HHC products on total-THC math regardless of how the scheduling question resolves. Federal litigation is not the only clock running.
For the underlying chemistry and legal distinctions, start with HHC vs THC: the legal difference, and for the closest product comparison, HHC vs delta-8.
Is HHC federally legal in 2026?
DEA's position, restated in an August 2026 Fourth Circuit brief, is that HHC is a Schedule I controlled substance and not hemp, because commercial HHC is synthesized rather than naturally occurring. No court has conclusively resolved the question, and the Fourth Circuit declined to stay the rule in June.
What did DEA's May 2026 rule change?
It gave HHC its own listing and drug code in Schedule I, separating it from the general tetrahydrocannabinols code. DEA characterizes this as an administrative tracking change with no substantive effect on HHC's status.
Does the December 11 hemp delay cover HHC?
On DEA's reading, no. The agency treats HHC as already scheduled because it is synthetic, independent of the hemp redefinition timetable. Delaying that timetable does not create an exemption DEA says never applied.
Is HHC a synthetic cannabinoid?
HHC occurs in trace amounts in cannabis, but commercial HHC is produced by hydrogenating hemp-derived CBD. DEA treats chemically converted cannabinoids as synthetically produced for Controlled Substances Act purposes.
Who is suing DEA over HHC?
Bluestar Operations, LLC in the Fourth Circuit and IHC Investments, Inc. in the Ninth Circuit. Both argue the 2018 Farm Bill's text covers hemp-derived cannabinoids produced by ordinary conversion processes.
What should HHC sellers do before November 12?
Inventory triage, COA verification for HHC and HHC-P content, processor and carrier policy checks, state scheduling review, and documentation of the sourcing and conversion chain. This is not legal advice — talk to your counsel.
This is regulatory journalism, not legal advice — talk to your counsel.
The Drug Enforcement Administration told a federal appeals court on Tuesday, August 11, 2026 that the hemp company challenging its treatment of hexahydrocannabinol has no right to be in court at all. In a brief filed in the U.S. Court of Appeals for the Fourth Circuit, DEA argued that Bluestar Operations, LLC lacks standing to petition for review of the agency's May 2026 rule, and that even if it had standing, it would lose. The filing is signed by DEA Administrator Terrance Cole.
The rule at the center of the case is narrow on its face. Until May 2026, HHC was tracked under the same DEA drug code as tetrahydrocannabinols generally. The rule gave HHC its own separate listing and its own code in Schedule I of the Controlled Substances Act.
DEA's brief leans hard on that narrowness. HHC, the agency wrote, “is a synthetic hallucinogenic drug that for decades has been included in schedule I under the Controlled Substances Act (CSA).” Assigning it a code is “a technical change that has no substantive effect on HHC's status as a schedule I substance.” Because the rule “imposes no new obligations or liabilities,” DEA argued, Bluestar has not “identified any injury traceable to the rule that can be remedied in this proceeding.”
The agency then made the argument that matters most to operators: “Even if this Court were to grant Bluestar's requested remedy and vacate the final rule, HHC still would be a schedule I substance as a THC.”
Here is the part the wire coverage does not spell out. DEA's position is structurally self-reinforcing. The agency says the rule changed nothing, therefore no one was injured by it, therefore no one can challenge it. But the reason HHC sellers believe they were injured is precisely the underlying classification that DEA says the rule merely restates — a classification that was never itself promulgated through a challengeable rulemaking.
Win or lose on the merits, that framing pushes the real question out of the appellate posture and into some future enforcement action, where a defendant argues product by product that its specific HHC is hemp. DEA said as much: “Bluestar remains free to argue that its HHC qualifies as hemp in an appropriate case.” For a business, an “appropriate case” means a seizure, a prosecution or a civil enforcement proceeding. That is a materially worse forum than a petition for review, and it is why this brief matters more than its procedural framing suggests.
DEA also conceded a point worth reading closely: “Bluestar does not even claim that the listing of HHC in schedule I is categorically unlawful. Bluestar claims only that its specific products are hemp and therefore exempt from schedule I.” The agency is right that this is a product-specific dispute. It is also the reason a favorable ruling for Bluestar would not settle the category.
Two petitions are live. Bluestar Operations, LLC is in the Fourth Circuit, which denied its request for a stay of the rule in June — the products stay in Schedule I while the case proceeds. IHC Investments, Inc. brought a parallel challenge in the Ninth Circuit. We covered both petitions when they were filed.
The circuit split potential is not accidental. Bluestar leans on a Fourth Circuit decision holding that hemp-derived THC-O-acetate is federally legal despite DEA's contrary view. IHC leans on the Ninth Circuit's 2022 delta-8 decision reading the 2018 Farm Bill's language expansively. Both petitions argue the major questions doctrine: that banning a category worth billions requires clear congressional authorization, not agency interpretation. In a reply this month, Bluestar said DEA is “unable to defend the merits of treating hemp-derived HHC as a Schedule I controlled substance — a position contrary to binding Circuit precedent.”
DEA's counter-position is a definitional one it has held since at least a 2023 letter from its Drug and Chemical Evaluation Section: HHC “does not occur naturally in the cannabis plant and can only be obtained synthetically.” In the rule itself the agency wrote that “tetrahydrocannabinols produced through chemical conversion, even when hemp derived, are considered synthetically produced” and fall outside the hemp exclusion. Commercial HHC is made by hydrogenating hemp-derived CBD, which puts essentially the entire commercial supply on DEA's side of that line. The Department of Health and Human Services concurred in the listing.
This is the sequencing consequence operators keep missing. Much of the industry is watching whether the hemp recriminalization date moves from November 12 to December 11, 2026 — the Senate has passed a delay, the House has not acted, and it is not law. Read the December 11 delay fight for the mechanics.
For HHC, the delay is beside the point. DEA's stated position is that HHC is Schedule I today, independent of any Farm Bill deadline, because it is synthetic. A delay to the hemp redefinition changes the date on which other cannabinoids lose their exemption. It does not confer an exemption HHC, on DEA's reading, never had. DEA underlined the asymmetry itself, telling the court Bluestar's theory “will soon be overtaken by events” because the coming recriminalization “will defeat whatever remains of Bluestar's claims.”
Translated: DEA thinks it wins on the calendar even if it loses in court. An HHC seller planning around December 11 is planning around the wrong risk.
The United States is not an outlier here, and that is worth knowing if you export. A United Nations drug control body added HHC to Schedule II of the 1971 Convention on Psychotropic Substances last year; the U.S. was the only country to abstain from that vote. Europe moved earlier and harder — see Europe's semi-synthetic cannabinoid crackdown and the current picture in the UK and EU.
Domestically, contrast the federal posture with what states do on their own timetable. Virginia's 2 mg per-package cap took effect August 15 and catches HHC products on total-THC math regardless of how the scheduling question resolves. Federal litigation is not the only clock running.
For the underlying chemistry and legal distinctions, start with HHC vs THC: the legal difference, and for the closest product comparison, HHC vs delta-8.
Is HHC federally legal in 2026?
DEA's position, restated in an August 2026 Fourth Circuit brief, is that HHC is a Schedule I controlled substance and not hemp, because commercial HHC is synthesized rather than naturally occurring. No court has conclusively resolved the question, and the Fourth Circuit declined to stay the rule in June.
What did DEA's May 2026 rule change?
It gave HHC its own listing and drug code in Schedule I, separating it from the general tetrahydrocannabinols code. DEA characterizes this as an administrative tracking change with no substantive effect on HHC's status.
Does the December 11 hemp delay cover HHC?
On DEA's reading, no. The agency treats HHC as already scheduled because it is synthetic, independent of the hemp redefinition timetable. Delaying that timetable does not create an exemption DEA says never applied.
Is HHC a synthetic cannabinoid?
HHC occurs in trace amounts in cannabis, but commercial HHC is produced by hydrogenating hemp-derived CBD. DEA treats chemically converted cannabinoids as synthetically produced for Controlled Substances Act purposes.
Who is suing DEA over HHC?
Bluestar Operations, LLC in the Fourth Circuit and IHC Investments, Inc. in the Ninth Circuit. Both argue the 2018 Farm Bill's text covers hemp-derived cannabinoids produced by ordinary conversion processes.
What should HHC sellers do before November 12?
Inventory triage, COA verification for HHC and HHC-P content, processor and carrier policy checks, state scheduling review, and documentation of the sourcing and conversion chain. This is not legal advice — talk to your counsel.
This is regulatory journalism, not legal advice — talk to your counsel.
